Infection with enterohemorrhagic Escherichia coli (EHEC)
is associated with food-borne outbreaks of diarrhea (47) , hemorrhagic colitis (28, 41, 42) , and the hemolytic uremic syndrome (17, 24, 28, 39) . One such outbreak occurred recently in the Pacific Northwest (3, 34) . A key characteristic of these EHEC strains is that they produce Shiga-like toxins (SLTs) (for reviews, see references 10, 17, 33, 52, and 53). These SLTs, also known as verotoxins (VT) (18) , inhibit protein synthesis by cleaving a specific adenine residue in the 28S subunit of eukaryotic rRNA (6) . They are multisubunit toxins that consist of one enzymatically active A subunit and five receptor-binding B subunits and are cytotoxic for Vero tissue culture cells (33) .
Two groups of SLTs that differ significantly in immunological reactivity have been described. They have been designated Shiga-like toxin type I (SLT-I) and Shiga-like toxin type II (SLT-II). The SLT-I group contains the prototype toxin SLT-1 in addition to Shiga toxin from Shigella dysenteriae type I. SLT-I and Shiga toxin differ by only one amino acid (49) and are considered to be the same toxin. SLT-I/Shiga toxin uses the glycolipid globotriaosylceramide (Gb3; Galotl-4 Galrl4Glc,B1-lCer) as the functional eukaryotic cell surface receptor (20, 23) . anti-SLT-I/Shiga toxin monoclonal or polyclonal antiserum (15) . Unlike the SLT-I/Shiga toxin group, the SLT-II group exhibits sequence and antigenic variation. SLT-II produced by EHEC 0157:H7 strains is considered the prototype toxin for this group, which also includes the toxin responsible for edema disease of swine (25, 29, 58) , SLT-IIv (recently renamed SLT-IIe [see Materials and Methods for discussion of nomenclature]). In contrast to SLT-II, SLT-IIv binds more avidly to globotetraosylceramide (Gb4; GalNAcI1-3Galo 1-4Gal,B 1- 4GlcP1-1Cer) than to Gb3 (4, 43) .
Since 1990, a number of new SLTs have been identified that are considered members of the SLT-II group on the basis of sequence homology and immunological cross-reactivity with SLT-II. These SLT-II group members include SLT-Ilvha (VT2vha), SLT-Ilvhb (VT2vhb), and SLT-IIc, all of which are nearly 97% homologous to SLT-1I at the deduced amino acid sequence level (14, 45) . Other SLT-II-related toxins have been described (8, 12, 21, 30, 37, 44, 54, 59 ), but many of these toxins were detected by PCR analysis and only a few have been isolated and sequenced.
Several clinical EHEC isolates that contain more than one copy of slt-II have been reported. Schmitt et al. described five such strains (45) , including E. coli 0157:H-strain E32511, which contains slt-II and slt-IIc, and E. coli 091:H21 strain B2F1, which contains slt-Ilvha and slt-Ilvhb (14) . We recently cloned and characterized three genes for SLTs from the EHEC 091:H21 isolate H414-36/89 (21) . Antigenic analysis showed that two of the toxins from EHEC H414-36/89 were SLT-II related and that one was similar to the prototype SLT-I1 toxin.
A number of epidemiological studies have correlated infection with EHEC strains that produce high levels of SLT and Table 2 describes the amino acid relationship among relevant SLT-II-related toxins used. The new nomenclature for SLT-II-related toxins that appear to be closely related to SLT-II by DNA hybridization and sequence homology and exhibit only minor variations in other properties is "SLT-IIc," and the name for the toxin produced by E. coli that causes edema disease in swine has been changed from SLT-IIv to SLT-Ile (58a). However, the original designations for the "SLT-IIc" toxins, SLT-IIvha, SLT-Ilvhb, and SLT-IIc, will be retained in this study so as to precisely identify the particular clones and toxin sequences. Collectively, these toxins will be called SLT-II-related toxins.
Media, enzymes, and biochemicals. Bacterial strains were routinely grown in Luria-Bertani medium (27) Mouse feeding and LD50 studies. The method for mouse feeding was described previously (56) . CD-1 male mice aged 5 to 6 weeks old (Charles River Laboratories, Wilmington, Mass.) were used throughout this study. Throughout each experiment, mice were given drinking water which contained streptomycin (5 g/liter) and ampicillin (5 g/liter) . Oral streptomycin treatment reduces the level of facultative anaerobic bacteria that normally colonize the mouse intestine (31) . The ampicillin was given orally to prevent segregation of plasmids that contained ampicillin resistance markers. A spontaneously streptomycin-resistant (Strr) E. coli K-12 strain [DH5co(Strr)] transformed with vector alone or with vector containing a cloned toxin gene was fed to groups of three to five mice at levels of approximately 101' CFU. Mouse death was monitored daily for 14 days. Kidneys were isolated from moribund mice or healthy controls for histological analysis. The specimens were fixed in 10% buffered formalin, processed routinely for histologic examination, and stained with hematoxylin and eosin.
The quantity of purified toxin required to kill mice was assessed by LD50 studies. Various dilutions of purified SLT-II or SLT-Ilvhb in 0.2 ml of sterile nonpyrogenic 0.9% saline (Kendall McGaw Laboratories, Inc., Irvine, Calif.) were administered intraperitoneally to groups of five CD-1 mice. Deaths were monitored daily, and LD50S were determined by the method of Reed and Muench (40) . The experiments reported here were conducted according to the principles set forth in the Guide for the Care and Use of Laboratory Animals (32). Toxin purification. Both SLT-II and SLT-Ilvhb were purified from E. coli DH5ot that contained the appropriate toxin gene on a high-copy pBluescript plasmid (Stratagene). Saturated overnight cultures of E. coli DH5ot/pJES120 (SLT-II) or E. coli DH5ox/pSQ543 (SLT-Ilvhb) were inoculated into a total of 6 liters of enriched medium (2% tryptone, 1% yeast extract, 0.5% NaCl, 0.2% glycerol). The bacteria were cultured for 24 h, harvested by centrifugation, and lysed by sonic disruption. The bacterial lysates were clarified by centrifugation and concentrated with 60% ammonium sulfate. The resultant crude toxin preparations were dialyzed against 0.05 M Tris (pH 7.0) (SLT-II) or 0.05 M Tris (pH 8.0) (SLT-Ilvhb), subjected to CL-6B DEAE-Sepharose anion-exchange chromatography (Pharmacia, Uppsala, Sweden) with the same buffer, and eluted with a 0 to 1.0 M NaCl gradient. The cytotoxic fractions were pooled and dialyzed against chromatofocusing starting buffer (for SLT-II, 0.025 M histidine-HCl [pH 6.2]; for SLTIlvhb, 0.025 M imidazole-HCl [pH 7.4]). The toxin preparations were then applied to a chromatofocusing column (Polybuffer-exchanger 94 [Pharmacia] ) that had been equilibrated with the appropriate starting buffer. Fractions were eluted from the column with Polybuffer 74-HCl (pH 4.0) (Pharmacia). The cytotoxic fractions were pooled and dialyzed against phosphate-buffered saline (PBS) and then subjected to immunoaffinity chromatography with monoclonal anti-SLT-II B subunit antibody (designated BC5BB12, kindly supplied by N. Strockbine, Centers for Disease Control, Atlanta, Ga. [5] ) as the adsorbent. Fractions were eluted from the immunoaffinity column with 0.1 M glycine (pH 2.8) and immediately neutralized with 50 .1I of I M Tris (pH 9.0). The cytotoxic activity and the homogeneity of each fraction were assessed by Vero cell cytotoxicity and denaturing polyacrylamide gel electrophoresis, respectively. The fraction(s) that contained the highly purified toxin protein was dialyzed against PBS and stored at 4°C. [50] ), ascitic fluid of monoclonal anti-SLT-II B subunit (designated BCSBB512, [5] ), and culture fluid of monoclonal anti-SLT-II A subunit (designated 2El [38] a Cytotoxicity values were determined on the cultures that were fed to the mice. The lowest level of detection for this assay was 102 CD50/ml. 6 Mice were fed approximately 10'0 CFU bacteria and monitored for death for 14 days. Each ratio represents pooled data from one to six experiments. mutant SLT-Ilvhb/N16DA24D was generated with the single mutant SLT-Ilvhb/N16D as the template and the A24D oligonucleotide as the mutagenic primer. All of the nucleotide changes used to generate the B subunit mutations were confirmed by DNA sequence analysis.
Toxin-receptor affinity analysis. The affinities of SLT-II and SLT-Ilvhb for Gb3 were determined by an in vitro binding assay done as previously described (43) except that purified Gb3 and purified SLTs were used instead of crude preparations of these reagents.
RESULTS
Virulence of E. coli DH5a producing SLT-II-related toxins in streptomycin-treated, orally infected mice. Recent studies in our laboratory demonstrated that both EHEC 091:H21 strains B2F1 and H414-36/89 have LD50s of less than 10 bacteria in orally infected, streptomycin-treated mice (21) . Both of these 091:H21 strains contain two copies of slt-TI-related toxin operons (14, 21) . Furthermore, passive immunization of mice with anti-SLT-II antibody prior to oral inoculation with B2F1 or H414-36/89 protects mice from death (21) . These data indicate that production of SLT-II-related toxins is critical for the virulence of these strains in mice. To determine whether production of SLT-II-related toxin by an E. coli K-12 strain was sufficient to cause the death of orally infected mice, ampicillinresistant plasmids that contained slt-IIvha, slt-Ilvhb, or slt-IIc were separately transformed into E. coli DH5ot(Strr) and fed to mice treated with streptomycin and ampicillin. Production of the SLT-II-related toxins by E. coli DH5a(Strr) was lethal for the orally inoculated mice (Table 3 , experiment 1). Moreover, mice that were fed E. coli DH5ca(Strr) that elaborated SLT-IIrelated toxin developed renal lesions similar to those found in mice that were fed the 091:H21 strains (Fig. 1) Vero CD50 SLT-TT per ml were required for these recombinant strains to be lethal in the orally inoculated mice. To assess the relative oral toxicity of the nearly homologous (Table 2) SLT-IT-related toxins in mice, E. coli DH5ot(Strr) strains that produced lower levels of these toxins, as determined by Vero cell cytotoxicity, were fed to streptomycin-treated mice (Table  3 , experiment 2). These toxin-producing E. coli DH5ox(Strr) strains were constructed by cloning the slt-Ilvha and slt-Ilvhb toxin operons into lower-copy-number vectors or into pBluescript vectors in the reverse orientation of the P10C promoter ( Table 1) . Results from this set of feeding experiments demonstrated that E. coli DH5ot(Strr) strains that produced SLT-IT-related toxins at Vero cell cytotoxicity titers of 5 x 102 to 1 x 103 Vero CD50/ml remained lethal in mice (pSQ12, pCKS120 [ Table 3 ]). The toxin-expressing strains had an apparent threshold of lethality at Vero cell cytotoxicity levels of approximately 102 (pSQ549 [Table 3 ]). By contrast, E. coli DH5ot(Strr) strains that made SLT-I1 were consistently lethal only when the Vero CD50 per milliliter produced were 107 (pJES120 [Table 3 ]).
Specific activity of purified SLT-Ilvhb on Vero cells and in mice given intraperitoneal injections. One explanation for the observation that E. coli DH5ot(Strr) transformants that produce 102 to 103 Vero CD50 of SLT-IIvha, SLT-Ilvhb, or SLT-IIc per ml kill orally inoculated mice, whereas E. coli DH5oa(Strr) transformants that make as much as 105 Vero CD50 of SLT-IT per ml fail to do so, is that the toxins differ in specific activity at the in vitro or in vivo level, or both. To test this hypothesis, SLT-Ilvhb and SLT-T1 were purified and the specific activities of the toxins were compared on Vero cells and in CD-1 mice. SLT-Ilvhb was selected for purification because SLT-ITvha, SLT-IIvhb, and SLT-IIc have identical B subunit sequences and a clone of slt-TTvhb that produced high levels of toxin was available. The in vitro specific activity of SLT-II on Vero cells was approximately 5 pg/CD50, a value comparable to published results (60) . However, the Vero cell specific activity of purified SLT-Ilvhb was about 100-fold lower than that of SLT-TI (approximately 500 pg/CD50 for three SLT-IIvhb toxin preparations). When the purified toxins were intraperitoneally injected into CD-1 mice, SLT-11 and SLTITvhb were equally toxic. The in vivo specific activity of both SLT-II and SLT-Ilvhb was 1 to 2 ng/LD501. Thus, SLT-I1 was more toxic for Vero cells than SLT-Ilvhb was, but the toxins were equally toxic in mice. Therefore, the apparent difference in the in vivo toxicity of E. coli DH5oL(Strr) transformants that produce SLT-TI-related toxins versus SLT-II reflects the use of Vero CD50 as a measure of activity.
Comparison of the ratio of Vero cell active toxin (as measured by CD50) to total toxin (as measured by immunoreactivity) in crude preparations of SLT-II-related and SLT-II toxins. One explanation for the lower specific activity of SLT-II-related toxins on Vero cells is that the ratio of Vero cell active toxin to Vero cell inactive toxin is lower for the SLT-II-related toxins. A two-step experimental approach was used to test this hypothesis. First, the amount of toxin antigen per unit protein in crude extracts of SLT-1I-related and SLT-II toxins was compared by immunoblot analysis with a monoclonal antibody specific for the A subunit of SLT-TT. This monoclonal antibody was chosen as a probe because minor amino acid changes in the A subunit of SLTs appear to cause little or no variation in the reactivity of the toxins with antibodies (13) . As a control, the immunoreactivities of purified SLT-II and purified SLT-Ilvhb were compared and found to be similar. This latter observation supports our supposition that the two toxins react equally well with this monoclonal antibody (Fig. 2) in the immunoblot assay. The crude toxin preparations from E. coli DH5at that expressed SLT-II(pJES120), SLT-Ilvha-(pSQ343), or SLT-Ilvhb(pSQ543) and produced 1 x 107, 5 x 104, and 5 x 105 Vero CD5(/ml, respectively, appeared to contain similar amounts (within a twofold difference) of toxin antigen (Fig. 2) Next, the cytotoxic activity (toxicity) of crude lysates was compared with the cytotoxic activity of the lysates that remained after incubation with antibody (the latter is designated antigen unit) to determine whether toxin that was inactive on Vero cells was present in the lysates. The ratio of toxicity to antigen unit indicated whether most of the toxin present was active on Vero cells (high ratio) or whether a significant amount of the toxin was inactive on Vero cells (low ratio), since high levels of inactive toxin would titrate the neutralizing antibody and result in a low ratio. As demonstrated in Table 4 , the cytotoxic activity (CD50) per antigen unit was significantly higher for SLT-1I than for SLT-IIvhb or SLT-IIc. For the assays summarized in Table 4 , we used either monoclonal antibody to the SLT-1I B subunit or polyclonal antisera to SLT-II. These antibodies were selected because they neutralize cytotoxicity more effectively than do anti-SLT-1I A subunit monoclonal antibodies (45) . Nonetheless, the CD5orantigen unit ratios were also significantly higher for SLT-II than for the SLT-1i-related toxin preparations when the immunoreactivity assays were done with monoclonal antibody to the SLT-II A subunit (data not shown). Together, the results described in this section indicate that per microgram of toxin protein SLT-II is more Vero cell active than are SLT-II-related toxins. One caveat to this conclusion is that the SLT-II-related toxins may not react as well in this type of immunoreactivity assay with any antisera elicited against SLT-LI.
Identification of amino acids in the SLT-Ilvhb and SLT-IIc B subunits responsible for reduced Vero cell activity. As illustrated in Table 2 , there are four amino acid differences between SLT-II and SLT-Ilvha/SLTvhb in the A subunit and two amino acid differences in the processed B or receptorbinding subunit (14) . However, SLT-IIc, which has the same in vitro phenotype as SLT-Ilvha/SLT-IIvhb, is identical to SLT-II in the A subunit and to SLT-Ilvha/SLT-Ilvhb in the processed B subunit (45) . To determine whether one or both of the amino acid differences in the B subunit of these toxins is integral to the differential cytotoxic phenotype of the SLT-IIrelated toxins, we created two single and one double amino acid substitution(s) in SLT-Ilvhb and two single mutations in SLT-IIc. These mutations, SLT-IIvhb/N16D, SLT-IIvhb/ A24D, SLT-IIvhb/N16DA24D, SLT-IIc/N16D, and SLT-IIc/ A24D, were designed to make the toxins more like SLT-II at the amino acid level and therefore correspond to the amino acid codons present in the mature B subunit of SLT-LI at those positions. Toxin preparations from E. coli DH5ot transformed with the B subunit mutants cloned into pBR328 were subjected to cytotoxicity and immunoreactivity analysis ( Table 4 ). The N16D mutation in both SLT-Ilvhb and SLT-IIc resulted in a 200-fold increase in cytotoxicity, whereas the A24D mutation had little or no effect on SLT-II-related toxin cytotoxicity levels. Similarly, the N16D mutation but not the A24D mutation altered the cytotoxin immunoreactivity profile of the SLT-II-related toxins. The CD50/antigen unit ratios (the ratio of cytotoxicity to cytotoxicity after incubation with antisera) were low for the A24D mutants and the parent SLT-II-related toxins but much higher for the N16D mutants, the SLT-Ilvhb/ N16DA24D mutant, and the prototype SLT-II toxin. The absolute values for the ratios depended on the specificity of the antiserum and the arbitrarily chosen standardized dose for that antiserum. Preliminary mouse-feeding experiments were undertaken with strains expressing the mutant toxins; however, these experiments were terminated after we found that SLTIlvhb and SLT-II have the same specific activity in vivo (see (Fig. 3) . Thus, SLT-II had a fivefold-higher affinity for Gb3 in this assay system.
DISCUSSION
Three principal conclusions were inferred from this study of SLT-II and SLT-II-related toxins produced by EHEC. First, the synthesis of these toxins by an avirulent, laboratory-derived E. coli K-12 strain was sufficient to cause kidney damage in and kill orally infected, streptomycin-treated mice. Thus, toxin alone is the key determinant of EHEC pathogenicity in this mouse model. Second, the type of SLT-II produced by an EHEC strain does not appear to affect the mouse virulence of the strain because SLT-II and SLT-II-related toxins when purified and injected parenterally into mice had comparable in vivo specific activities. This conclusion does not rule out the possibility that more SLT-II-related toxin than SLT-II is produced in vivo by wild-type EHEC. Third, more SLT-IIrelated toxin antigen than SLT-II toxin antigen is required to produce I CD50 on Vero cells. This lower specific cytotoxic activity of SLT-II-related toxin on Vero cells reflects the amino acid at position 16 of the B subunit and may be a consequence of the lower affinity of binding to Gb3 on Vero cells.
Our observation that purified SLT-Ilvhb had a lower specific cytotoxic activity on Vero cells than did the prototype SLT-II toxin differs from the findings reported by Takeda and colleagues (35) . These investigators found that toxin purified from strain B2F1 (presumably a mixture of SLT-Ilvha and SLTIlvhb) has a Vero cell specific activity of 5.9 pg/CD50 (35) , a value that is similar to the specific activity of their preparation of SLT-II (60), whereas we found the specific activity of SLT-Ilvhb to be approximately 500 pg/CD50. The discrepancy between our findings and those of Oku et al. (35) may reflect differences in the Vero cell lines used in the two laboratories. Despite these differences in cytotoxicity results, it should be emphasized that the in vivo specific activity of the toxin preparation purified from strain B2F1 by Oku et al. (35) (2.7 ng/LD50) is comparable to that obtained for SLT-Ilvhb in this study (1 to 2 ng/LD50).
The finding that Asn-16 in the SLT-Ilvhb and SLT-IIc B subunits was responsible for the reduction in cytotoxicity and altered immunoreactivity of the SLT-II-related toxins on Vero cells when compared with SLT-II suggests that Asn-16 is involved in carbohydrate binding. That A subunit differences between SLT-II and the SLT-II-related toxins are not important for the cytotoxicity and immunoreactivity profiles is indicated by the fact that SLT-IIc is identical to SLT-II in the A subunit (Table 2 ) but has the same cytotoxicity and immunoreactivity profile as SLT-Ilvha/SLT-Ilvhb (Table 4 ). We also found that mutant SLT-IIc/N16D is phenotypically similar to SLT-Ilvhb/NI6D. Therefore, the only difference observed between SLT-Ilvha/SLT-Ilvhb/SLT-IIc and SLT-II that is relevant to cytotoxicity appears to be the Asn-16 residue in the B subunit. We are currently purifying the mutant toxins for further receptor-binding analysis.
Additional lines of evidence in support of the importance of the amino acid at position 16 in SLT toxin binding to receptors are the site-directed mutagenesis studies of Jackson et al. (16) and the X-ray crystallographic results of Stein et al. (48) . Both studies indicate that position 17 in the Shiga toxin/SLT-I B subunit (which corresponds to position 16 in the SLT-IIrelated toxins) is involved in toxin-receptor binding. The SLT-II-related toxins, SLT-Ilvha, SLT-Ilvhb, and SLT-IIc, contain an uncharged asparagine residue at position 16, whereas Shiga/SLT-I and SLT-II have a negatively charged aspartic acid residue at this location. The lack of a negatively charged amino acid at position 16 in the SLT-II-related toxins may affect the electrostatic interaction between the amino acids in the putative toxin-receptor binding cleft and result in the observed reduction in toxin-receptor binding. Additional studies which indicate that this region of the B subunit is important in receptor binding include those of Tyrell et al. (55) . These investigators found that a D18N mutation in the B subunit of SLT-I resulted in binding of the mutant toxin to Gb4 as well as to the functional receptor Gb3. It should be noted that Ito et al. also demonstrated an antigenic dissimilarity between SLT-II (VT2) and SLT-Ilvha (VT2vh) (13) . However, in contrast to our findings, these investigators attributed the antigenic dissimilarity (which they observed by Ouchterlony double-gel diffusion analysis) between the two toxins to the alanine residue at position 24 in the B subunit of SLT-Ilvha (13).
Several explanations are possible for the disparity we observed between the in vitro cytotoxic activity of SLT-II-related toxins and the activity of the toxins in animals. One possible reason for the apparent relative inactivity of the SLT-II-related toxins on Vero cells is the decreased affinity of these toxins for the SLT-II functional receptor, Gb3 (Fig. 3) . However, SLT-I and SLT-II also differ in binding affinity for Gb3 but do not exhibit differences in specific activity on Vero cells (51) . An alternative reason for the reduced toxicity of SLT-II-related toxins on Vero cells is that the functional receptor that leads from binding to internalization of these toxins is not Gb3 but another receptor that is present at low levels on our Vero cells. A corollary might be that the SLT-II-related toxins do bind Gb3 on Vero cells but are not internalized efficiently. Whatever the explanation for these in vitro findings, the toxicity of SLT-II-related toxins is unimpaired in animals.
